EHR alert increases hepatitis C screening in elderly patients

The implementation of an electronic health record (EHR) alert system increased screenings for hepatitis C in geriatric patients, according to a study published in Hepatology.

Screening for hepatitis C can catch the disease early—giving patients a better chance at receiving effective treatment. Many baby boomers, however, remain unscreened. This study evaluated if an EHR alert for the hepatitis C virus (HCV) could increase screening rates in elderly patients.

The study implemented a EHR system informing primary care physicians to perform hepatitis screenings if patients were born between 1945 and 1965, lacked a prior hepatitis C infection and did not have prior hepatitis C testing.

Results of 52,660 elderly patients, 28 percent of which were screened, found screening rates increased from 7.6 percent before EHR alerts to 72 percent a year after implementation. Of the 53 newly diagnosed patients, 20 had begun treatment, 11 had advanced fibrosis or cirrhosis and nine had a long-term viral response.

“Implementation of an EHR–based prompt increased hepatitis C virus screening rates among baby boomers in primary care by five-fold due to efficiency in determining needs for hepatitis C virus screening and workflow design,” concluded first author Monica Konerman, MD, of the Ann Arbor-based University of Michigan, and colleagues. “Streamlined access to specialty care enabled patients with previously undiagnosed advanced disease to be cured. This intervention can be easily integrated into EHR systems to increase hepatitis C virus diagnosis and linkage to care.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.